Clinical trials: Atezolizumab
Small Cell Lung Cancer Extensive Stage, Thoracic Radiotherapy
Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease
This is a multicenter phase 2 clinical trial to investigate the treatment efficacy and feasibility of combining thoracic radiotherapy (TRT) with the IMpower133 regimen in the upfront treatment of ED SCLC patients.
- Trial name
- TREASURE (NCT04462276)
- Testing
- Atezolizumab, thoracic radiotherapy (TRT)
- Where
- 20 sites in Austria, Germany
- Volunteers
- 68 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Advanced Melanoma
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
The purpose of this study is to evaluate the efficacy and safety of tebentafusp-based regimens, including tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of…
- Trial name
- NCT05549297
- Testing
- Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice
- Where
- 82 sites in United States, Australia and 10 more
- Volunteers
- 540 people
- Sponsor
- Immunocore Ltd
Non Small Cell Lung Cancer Metastatic
Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer
This study includes the additional use of radiation therapy in combination immunotherapy in order to determine whether the radiation may improve the response of non-small cell lung cancer to immunotherapy and to monitor any side…
- Trial name
- NCT03035890
- Testing
- Radiation, Immuno-Therapeutic Agent
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- West Virginia University
Non-small Cell Lung Cancer
Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC
This randomized, Phase III, multicenter, open-label study designed to evaluate the efficacy of Atezolizumab in combination with carboplatin, paclitaxel, bevacizumab compared with treatment with pemetrexed, cisplatin in…
- Trial name
- NCT03991403
- Testing
- Atezolizumab(Tecentriq), Pemetrexed, Bevacizumab
- Where
- South Korea
- Volunteers
- 228 people
- Sponsor
- Samsung Medical Center
Triple Negative Breast Cancer, Stage IV Breast Cancer
Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer
This randomized phase II trial studies how well carboplatin with or without atezolizumab works in treating patients with stage IV triple negative breast cancer.
- Conditions
- Triple Negative Breast Cancer, Stage IV Breast Cancer, HER2 Negative, Invasive Breast Cancer
- Trial name
- NCT03206203
- Testing
- Atezolizumab, Carboplatin, Laboratory Biomarker
- Where
- 6 sites in United States
- Volunteers
- 106 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Bladder Cancer
Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer
This is an open-label phase II study assessing the activity of cabozantinib combined with atezolizumab in patients with resectable muscle-invasive urothelial carcinoma who are ineligible for cisplatin-based therapy or decline…
- Trial name
- ABATE (NCT04289779)
- Testing
- Cabozantinib, Atezolizumab, Cystectomy
- Where
- 6 sites in United States
- Volunteers
- 46 people
- Sponsor
- Deepak Kilari
Breast Cancer
Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer
This is a multi-centre, open label, phase 2, randomised controlled trial of patients with advanced triple negative breast cancer (TNBC) who have received no more than one line of chemotherapy (not including neoadjuvant or…
- Trial name
- AZTEC (NCT03464942)
- Testing
- SABR, Atezolizumab
- Where
- Australia
- Volunteers
- 54 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Solid Tumor
A MolEcularly Guided Anti-Cancer Drug Off-Label Trial
This is a prospective, open-label, non-randomized combined basket- and umbrella trial divided in two parts; a limited feasibility-oriented part 1 including 154 patients and 3 treatment cohorts and part 2 that will include an…
- Trial name
- MEGALiT (NCT04185831)
- Testing
- Atezolizumab, Everolimus, Cobimetinib
- Where
- 3 sites in Sweden
- Volunteers
- 167 people
- Sponsor
- Uppsala University Hospital
Neoplasms, Solid Tumors
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available…
- Conditions
- Neoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer
- Trial name
- NCT02091141
- Testing
- Trastuzumab, Pertuzumab, Erlotinib
- Where
- 60 sites in United States
- Volunteers
- 673 people
- Sponsor
- Genentech, Inc.
Hepatocellular Carcinoma Resectable
Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer
This is a single-center, prospective, non-randomized, open-label, phase II clinical trial aiming to evaluate the efficacy and feasibility of using patient-derived tumor organoid drug sensitivity testing (ODST) to guide…
- Trial name
- NCT07363356
- Testing
- Organoid Drug Sensitivity Testing-Guided Therapy
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Unresectable Hepatocellular Carcinoma
Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001)
This is a retrospective, multicenter, real-world cohort study designed to evaluate the effectiveness and safety of atezolizumab plus bevacizumab (Atezo+Bev) combined with various locoregional therapies (LRTs), including…
- Trial name
- ISMIO001 (NCT07204327)
- Testing
- Atezo+Bev plus Locoregional Therapy
- Where
- China
- Volunteers
- 1,136 people
- Sponsor
- Zhongda Hospital
Early-stage Breast Cancer, HER2-positive Breast Cancer
Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer
This is a phase 2 study evaluating medical treatment before surgery in HER2-amplified early breast cancer patients. Patients receive chemotherapy with HER2-targeted antibodies and are randomised to receive the checkpoint…
- Trial name
- PREDIXIIHER2 (NCT03894007)
- Testing
- Docetaxel, Carboplatin, Trastuzumab
- Where
- 8 sites in Sweden
- Volunteers
- 6 people
- Sponsor
- Renske Altena
Unspecified Adult Solid Tumor, Protocol Specific
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
A modular, first time in human, open label, multiple dose, accelerated escalation with cohort expansion study of the safety and pharmacokinetics of intravenous infusion of CP-506, a tumor agnostic Hypoxia Activated Prodrug in…
- Trial name
- NCT04954599
- Testing
- CP-506, Carboplatin, Immune checkpoint inhibitor
- Where
- 5 sites in Belgium, Netherlands and 1 more
- Volunteers
- 126 people
- Sponsor
- Maastricht University Medical Center
Hepatocellular Carcinoma Non-resectable
Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab
Aim of the study is to evaluate the efficacy of up-front atezolizumab/ bevacizumab (Atezo/Bev) followed by on-demand selective transarterial chemoembolization (sdTACE) and of initial synchronous treatment with TACE and Atezo/Bev…
- Trial name
- DEMAND (NCT04224636)
- Testing
- Atezolizumab Injection, Bevacizumab Injection
- Where
- 7 sites in Germany
- Volunteers
- 106 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Cutaneous Squamous Cell Carcinoma
Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma
The purpose of this research is to evaluate whether the administration of atezolizumab before surgical resection of the tumor is feasible and to evaluate the treatment response, safety, and tolerability of atezolizumab.
- Trial name
- NCT04710498
- Testing
- Atezolizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Brain Tumor, Non Small Cell Lung Cancer
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA…
- Trial name
- LIMITLESS (NCT05317858)
- Testing
- Blood Brain Barrier Opening - Oncology, Pembrolizumab, Atezolizumab
- Where
- 16 sites in United States, Canada and 1 more
- Volunteers
- 96 people
- Sponsor
- InSightec
Adverse Effect, Renal Toxicity
Study of Adverse Renal Effects of Immune Checkpoints Inhibitors
Renal toxic events related to Immune Checkpoints Inhibitors therapy (Nivolumab, Pembrolizumab, Atezolizumab and Ipilimumab) have been recently reported. These were immune-allergic acute interstitial nephritis.
- Trial name
- ImmuNoTox(INT) (NCT03316417)
- Testing
- Renal Tolerance to Immunotherapy
- Where
- France
- Volunteers
- 353 people
- Sponsor
- Hospices Civils de Lyon
Non-Small Cell Lung Cancer
PD-L1 Expression in Lung Cancer
This study will measure PD-L1 expression in metastatic NSCLC (primary tumour and metastatic lesions) using [99mTc]-NM-01 SPECT/CT and compare to PD-L1 percentage expression determined by immunohistochemistry (IHC).
- Trial name
- PELICAN (NCT04992715)
- Testing
- [99mTc]-NM01 SPECT/CT
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- NanoMab Technology (UK) Limited
Non-squamous NSCLC
Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
This study aimed to explore the efficacy of Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Non-squamous NSCLC.
- Trial name
- NCT05261438
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Hunan Province Tumor Hospital
Extensive Stage-small Cell Lung Cancer
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small…
- Trial name
- NCT06362252
- Testing
- Ifinatamab deruxtecan, Atezolizumab, Carboplatin
- Where
- 58 sites in United States, France and 2 more
- Volunteers
- 123 people
- Sponsor
- Daiichi Sankyo